Member Info for potnak

but they are going for a P1a which, along with safety, will monitor certain Immune biomarkers. This should give us an idea of efficacy in later trials. A big pharma who wants to partner might want to tweak the design. Or run it in their own country even. Pronai (Sierra) licenced SRA737 not long after the P1 trial started but then were bound by the trial design. IMO this hampered the development and gave Sierra a way to not pay milestones. Tim and the board will not want this scenario to happen again. If someone is waiting in the wings to licence the compound, they will want input into the design of the trial but will have to come up with the cash before the CTA is submitted and committed to. I think this has been the plan for the last 18 months and bringing the HNWI on board strengthens this position. We are IMO nearing a pivot point that will decide the roadmap for the next couple of years. It is getting exciting now.

Yes, that was my point. They said, back in March that they were working with experts to design the trial. Presumably, this includes peer reviews? They also said they were progressing with the manufacturing. IMO, the manufacturing is the only piece of the jigsaw that could delay the CTA. I believe we are close to the answers we need. I also believe that there is a bit of gamification going on. A do a deal now and design your own trial or we will do it our way scenario.

We need GSK to acknowledge SRA737 to get this moving. As others have said. There are bigger things going on at GSK. I don't think we will get any clarity until after the split. I think a perfect little storm is brewing that could see us back at £5 (10p old money) if the news drops on consecutive weeks or days even.

I'd not seen that before HBD, thank you. You'd think as we knew we didn't need funding that we at least started from that point, especially when they gave us an update back in March on the tox results RNS. It must be close by now. The only fly in the ointment is the manufacturing part. I don't think we have had an update on this? I guess if the CTA is granted then we will have our answer.

Maf, I'm not sure they will acknowledge SRA737 in the first RNS. We might have to wait until the pipeline update that Billy B was talking about. If you look at GSK RNS page, they only do RNS on pipeline drugs when a significant milestone is reached. I'm sure there is a plan for SRA737 but GSK shareholders aren't baying for it or even know it exists.

What part of the Sierra sale is RNSable to Sareum shareholders, Utar? A company bought a company who happens to have a stalled deal with an organisation that Sareum had a collaboration with. Sounds a bit desperate to potential partners. We will get a note when GSK release a note mentioning SRA737.

FWIW. I think something is being worked on now and this can't be finalised until we have clarity with 737. There is no technical or clinical reason why a CTA should take this long complete. I think it is being held back along with the trading statement that is due. I think we are reaching a pivot point that we will cross in the next few weeks. Licence\TO or Do P1 ourselves. Some cash or even a direction of travel for 737 would help us walk away from a bad deal.

Billy, When posters here say we're developing a Covid pill. We're not. We do have do have some good data if someone else wants too though. Got to get through P1 before we are developing anything. It could be 2023 before we even know indication what we trial 1801 in. P1 end of this year, if successful, P1a in a named indication early next year. A buyout or chunky licence deal will put us all out of our misery.

The deal was between CRT and Pronai. The board have stated on numerous occasions that they have no influence and that they get news when we do. Tim and board will be waiting for a red dot just as we are. Its my bigest bug bear on here (this and the covid pill myth). We aren't owed any expalantion from Sierra or GSK. If anything, the Sareum Twiiter activist should be targeting the CRT, it's their deal and they wil know whats happening. For the record, I think GSK taking it is a good move for Sareum but Billy Bunter is correct, SRA737 will just become part of the GSK pipeline and we'll be scanning the trading updates for news. More of the same but with a much bigger budget to progress.

I'm still of the opinion that SRA737 is part of a bigger picture that is being worked on. In terms of 737, Sareum are just a bystander. It isn't our compound anymore, we are not the major stakeholder and GSK doesn't owe Sareum shareholders any explanation. However, there is some intrinsic value in SRA737 for Sareum, even at this stage. Maybe £200 million? This value will feature in any TO negotiations and is possibly dependent on it. It's good that 737 has a new home or even a foster home but confirmation of the next steps could add some significant value here. I reckon August is going to be awash with news.

They could buy out of the agreement with CPF (and SAR) it would cost them at least the remaining milestones and maybe some on top to cover lost royalties. It might be an option worth paying for when you consider the royalties alone could be worth a couple of hundred million a year if it gets to market. The question is would the CPF go for it? I think they would, all profit made goes back into cancer research anyway. Sareum would largely be a bystander in a deal like this. This has been the very scenario I've been thinking of. Low cost, carrying less risk but big rewards if it goes to market.

*****tone or Clitheroe?

For those who think the below links are a little too tenuous. Cast your mind back to this news in 2019. Gilead, Galapagos and Sareum all mentioned in the same article. Oh, and Galapagos still haven't spent that 5 billion dollars and Sareum still has an unpartnered TYK2. https://quoteddata.com/2019/07/trust-favourite-gilead-expands-deal-galapagos/

I'm half expecting a yes vote in this meeting will start a chain reaction for everything else Sareum. I still think everything is hinged on this deal. Sierra, GSK, Gilead and by assotiation, Galapagos. I may be completely wrong and probably am but it would explain a lot of things if i am right. Very exciting though.

Yes, we might see a nice bit of FOMO as Thursday comes and goes.

Aye but Dexamethasone is widly available, super safe, already standard care for many, many conditions and its about 8 quid a dose. 1801 would only be used on a subset of patients where Dexamethasone isn't a good fit. Not saying there isn't a need for 1801 in respiratory illness but I won't take Dexamethasones crown.

Yep, I agree Utar. The SP might go on a little run between now and Thursday. Of course, the news might not come by Thursday too but it definitely could be a buy-on rumour, sell-on news scenario. The FOMO will kick in at some point.

I have just had my second bout last week. Very mild, two days of feeling a bit off. It seems to be super transmissive though. I was in the Lakes with my running friends last weekend and 6 of them have tested positive in the last two days. I'm expecting more of them to do the same.

HBD I'd agrees with your TO stance. But as I said this morning. We don't need a TO to add value to the SP. We could easily get two licence deals worth billions in milestones and if SRA737 gets moving then each one of those could add £5 to the SP, even from here. That's why I think a 10 bagger from here is still an option, even without a TO. Realistically a TO now would be less that what SAR are worth or why do it? I'd stick my neck out and say every SAR investor will be in profit by Christmas.

When I first saw Thoths name. I immediately thought of Led Zeppelin.